Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Diageo plc (DEO) vs Mesoblast Limited (MESO) Price & Performance

Diageo plcTrade
Mesoblast LimitedTrade

Price performance (Past 24H)

Key statistics

Diageo plc vs Mesoblast Limited — how do they compare? Diageo plc trades at $94.2 (market cap $53.75B), while Mesoblast Limited trades at $16.68 (market cap $2.16B). The key difference: Diageo plc is far larger — about 24.9× Mesoblast Limited's market cap, and Diageo plc pays a 3.42% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals.

DEOMESO
Market Cap
$53.75B$2.16B
Sector
TechnologyTechnology
52-Week High
$115.33$20.96
52-Week Low
$72.47$12.88
Enterprise Value
$73.25B$2.17B
Dividend Yield
3.42%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Diageo plc

Diageo (DEO) trades at $96.35, up 3.83% with bullish technical signals from moving averages. The company reported mixed FY2026 results with a 2% organic sales decline but 2% operating profit growth, supported by cost savings. Analyst consensus leans positive with 48.65% buy ratings, though valuation metrics appear elevated with a P/E of 31.16. Recent news highlights a $1 billion cost-cutting plan and strategic focus on spirits and Guinness to drive turnaround.

The outlook is cautiously optimistic with management's restructuring program expected to improve margins and cash flow. Key risks include ongoing weakness in North American markets and competitive pressures. Wall Street sees potential upside with recent target increases, but investors should monitor execution of the turnaround plan amid challenging market conditions.

Mesoblast Limited

MESO trades at $15.94, up 2.05% today, with a bullish technical signal from moving averages but mixed oscillators. The company reported Ryoncil net revenues of $36 million for Q2 2026 (GlobeNewsWire, July 29, 2026), showing commercial traction, yet fundamentals reveal a net loss of -$102.14 million in 2025 with a negative net margin. Valuation metrics include a P/S of 30.52 and P/B of 3.76, indicating high growth expectations.

Outlook hinges on Ryoncil's expansion and pipeline progress, but risks include sustained losses and regulatory hurdles. Analysts are cautiously optimistic with 45% buy ratings, yet the stock faces volatility from earnings misses and high cash burn.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Diageo plc

Diageo is a global leader in beverage alcohol with an outstanding collection of brands including Johnnie Walker, Smirnoff, and Guinness. It operates a vast portfolio of spirits and beers across more than 180 countries.

Read more on DEO

About Mesoblast Limited

Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.

Read more on MESO